Registration and abstract submission for the inaugural New Frontiers in 3D Cell Culture-based Screening Technologies: Towards greater physiological relevance conference open today via the conference website. Conceived and organized by InSphero AG, the National Center for Advancing Translational Sciences (NCATS), part of the National Institutes of Health (NIH), the Centers for Alternatives to Animal Testing (CAAT), and Promega Corp., the conference will feature keynote presentations by Dr. Michael Gottesman of the NIH’s National Cancer Institute’s Center for Cancer Research, and Dr. Thomas Hartung of the Johns Hopkins Bloomberg School of Public Health and Director of CAAT.
The one-day symposium, to be held Thursday, October 13, 2016 at the Johns Hopkins University Charles Commons in Baltimore, Maryland, will feature sessions on drug discovery and toxicology, with invited presentations from Novartis, the Hubrecht Institute, Merck, and the NIH’s National Institute of Environmental Health Sciences (NIEHS). Additional speakers will be selected from attendee abstracts submitted for podium presentation, with abstracts for consideration due by August 1, 2016. Abstracts for poster presentations will be accepted until August 15, 2016.
Dr. Jens Kelm, Chief Technology Officer of InSphero AG and member of the New Frontiers Scientific Advisory Board, says the conference fills what has been a clear gap in scientific forums by focusing on a global view of 3D cell culture technologies. “The goal of this new conference is to assemble an international forum of leaders in the field of 3D tissue models. We aim to offer a balanced perspective of state-of-the-art systems, their adoption and implementation in drug discovery and safety testing, and potential regulatory hurdles to consider as 3D models become standardized and more mainstream.” Kelm notes that the New Frontiers Conference plans to alternate between US and European host cities on an annual basis.